Treatment Access Solution
A collaboration with Novartis
The Max Foundation’s long-standing shared-values partnership with Novartis was first established in 2001 through the Glivec® International Patient Assistance Program, commonly known by its acronym GIPAP. GIPAP operates in specific low and middle-income countries providing access to Glivec® (imatinib) for people properly diagnosed with chronic myeloid leukemia ( ), gastrointestinal stromal tumors (GIST), and orphan indications for which Glivec has been approved. Eligible patients must meet medical and socio-economic criteria.
Additionally, the partnership between The Max Foundation and Novartis has expanded to include other treatment access models beyond GIPAP, including country-specific solutions. Patients must meet the medical criteria and program guidelines.